Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharmacology S1 Exam 5 > Immunomodulation Therapy; L2 (11-11-15) > Flashcards

Immunomodulation Therapy; L2 (11-11-15) Flashcards

1
Q

Glucocorticoids (Prednisone, Prednisolone) - Indications

  • __
  • To prevent __ rejection
  • To prevent __
  • Tx of __-release syndrome
  • Tx of a wide variety of ___ and __ diseases, e.g., RA, SLE, asthma, etc.
A

Glucocorticoids (Prednisone, Prednisolone) - Indications

  • Immunosuppression
  • To prevent graft rejection
  • To prevent GvHD
  • Tx of cytokine-release syndrome
  • Tx of a wide variety of autoimmune and inflammatory diseases, e.g., RA, SLE, asthma, etc.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Glucocorticoids (Prednisone, Prednisolone) - MOA

  • Activates the __ receptor transcription factor
  • Modifies expression of __ and other __regulatory genes
  • Suppresses active __ responses
A

Glucocorticoids (Prednisone, Prednisolone) - MOA

  • Activates the glucocorticoid receptor transcription factor
  • Modifies expression of cytokine and other immunoregulatory genes
  • Suppresses active immune responses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Glucocorticoids (Prednisone, Prednisolone) - Adverse Effects

  • MANY adverse effects
  • __glycemia
  • __tension
  • __lipidemia
  • Obesity
  • Diabetes
  • Poor __ healing
  • Mania and psychosis
  • Increased risk of __
A

Glucocorticoids (Prednisone, Prednisolone) - Adverse Effects

  • MANY adverse effects
  • Hyperglycemia
  • Hypertension
  • Hyperlipidemia
  • Obesity
  • Diabetes
  • Poor wound healing
  • Mania and psychosis
  • Increased risk of infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Glucocorticoids (Prednisone, Prednisolone) - Misc

  • Glucocorticoid dose should be __ reduced to minimize adverse effects
  • Glucocorticoids should NOT be __ __
A

Glucocorticoids (Prednisone, Prednisolone) - Misc

  • Glucocorticoid dose should be gradually reduced to minimize adverse effects
  • Glucocorticoids should NOT be withdrawn abruptly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Azathioprine - Indications

  • __
  • To prevent __ rejection
  • To prevent __
  • Tx of __ diseases
A

Azathioprine - Indications

  • Immunosuppression
  • To prevent graft rejection
  • To prevent GvHD
  • Tx of autoimmune diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Azathioprine - MOA

  • __
  • Converted to _-__ by __
  • Inhibits de novo __ synthesis
  • Incorporated into DNA and causes __ base mispairing -> apoptosis
  • Inhibits __ co-stimulation
A

Azathioprine - MOA

  • Prodrug
  • Converted to 6-MP by HGPRT
  • Inhibits de novo purine synthesis
  • Incorporated into DNA and causes SS base mispairing -> apoptosis
  • Inhibits CD28 co-stimulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Azathioprine - Adverse Effects

  • __penia/__penia
  • __toxicity
  • Increased risk of __
  • Increased risk of __
A

Azathioprine - Adverse Effects

  • Leukopenia/thrombocytopenia
  • Hepatotoxicity
  • Increased risk of infections
  • Increased risk of malignancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Azathioprine - Misc

-Interacts with __-__ drugs (__ and __) -> __ [azathioprine] -> increased __

A

Azathioprine - Misc

-Interacts with anti-gout drugs (allopurinol and febuxostat) -> increased [azathioprine] -> increased toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mycophenolate Mofetil - Indications

  • __
  • To prevent __ rejection
  • To prevent __
  • Tx of __ diseases
A

Mycophenolate Mofetil - Indications

  • Immunosuppression
  • To prevent graft rejection
  • To prevent GvHD
  • Tx of autoimmune diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mycophenolate Mofetil - MOA

  • __
  • Converted to __ __
  • Inhibits __ __ (IMPDH) type II (selectively expressed in __) -> inhibition of __ nucleotide synthesis - no __ pathway in lymphocytes
A

Mycophenolate Mofetil - MOA

  • Prodrug
  • Converted to mycophenolic acid
  • Inhibits inosine monophosphatedehydrogenase (IMPDH) type II (selectively expressed in lymphocytes) -> inhibition of purine nucleotide synthesis - no salvage pathway in lymphocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Mycophenolate Mofetil - Adverse Effects

  • __penia/anemia
  • __ (male/female)
  • Increased risk of __
  • Increased risk of __

-RARE - __ __ __ __ __ (PML) - fatal viral disease caused by reactivation of JC virus

A

Mycophenolate Mofetil - Adverse Effects

  • Leukopenia/anemia
  • Teratogenic (male/female)
  • Increased risk of infections
  • Increased risk of malignancy

-RARE - Risk of Progressive Multifocal Leukoencephalopathy (PML) - fatal viral disease caused by reactivation of JC virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mycophenolate Mofetil - Misc

-Contraindicated in __, women who wish to __ __, and men who wish to __ __

A

Mycophenolate Mofetil - Misc

-Contraindicated in pregnancy, women who wish to become pregnant, and men who wish to become fathers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Indications

  • __
  • To prevent __ rejection
  • To prevent __
  • Tx of __ diseases
A

Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Indications

  • Immunosuppression
  • To prevent graft rejection
  • To prevent GvHD
  • Tx of autoimmune diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Calcineurin Inhibitors (Cyclosporin, Tacrolimus) - MOA

  • Cyclosporin and tacrolimus bind __ and __, respectively, to form inhibitory complexes
  • __/cyclosporin and __/tacrolimus complexes inhibit the Ca2+-regulated phosphatase, __
  • Inhibition of __ inhibits the activation of the __ transcription factor, which is involved in regulating the expression of IL-__ and multiple other immunoregulatory genes
  • Potently inhibit the T-cell immune response by inhibiting signal __
A

Calcineurin Inhibitors (Cyclosporin, Tacrolimus) - MOA

  • Cyclosporin and tacrolimus bind cyclophilin and FKBP, respectively, to form inhibitory complexes
  • Cyclophilin/cyclosporin and FKBP/tacrolimus complexes inhibit the Ca2+-regulated phosphatase, calcineurin
  • Inhibition of calcineurin inhibits the activation of the NFAT transcription factor, which is involved in regulating the expression of IL-2 and multiple other immunoregulatory genes
  • Potently inhibit the T-cell immune response by inhibiting signal 1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Adverse Effects

  • **__**
  • __tension
  • __toxicity/tremor
  • Glucose intolerance ( __ > __ )
  • Hyperlipidemia ( __ > __ )
  • Hypertrichosis (__)
  • Alopecia (__)
  • Increased risk of __
  • Increased risk of __
A

Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Adverse Effects

  • **Nephrotoxicity**
  • Hypertension
  • Neurotoxicity/tremor
  • Glucose intolerance ( T > C )
  • Hyperlipidemia ( C > T )
  • Hypertrichosis (C)
  • Alopecia (T)
  • Increased risk of infections
  • Increased risk of malignancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Misc

  • Metabolized by CYP3A4 -> MANY drug interactions
  • 3A4 inhibitors promote __ drug levels -> increased risk of __
  • 3A4 inducers promote __ drug levels -> increased risk of __ rejection
A

Calcineurin Inhibitors (Cyclosporine, Tacrolimus) - Misc

  • Metabolized by CYP3A4 -> MANY drug interactions
  • 3A4 inhibitors promote increased drug levels -> increased risk of toxicity
  • 3A4 inducers promote decreased drug levels -> increased risk of graft rejection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

mTor Inhibitors (Sirolimus, Everolimus) - Indications

  • __
  • To prevent __ rejection (but NOT __, NOT __)
  • To prevent __
  • Included in __ stents to inhibit re__
A

mTor Inhibitors (Sirolimus, Everolimus) - Indications

  • Immunosuppression
  • To prevent graft rejection (NOT lung, NOT liver)
  • To prevent GvHD
  • Included in arterial stents to inhibit restenosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

mTor Inhibitors (Sirolimus, Everolimus) - MOA

  • Drugs form complex with __
  • __/drug complex inhibits IL-__ mediated activation of mTor kinase (T-cell signal __)
  • Inhibits IL-__ stimulated protein synthesis, cell proliferation, and survival
A

mTor Inhibitors (Sirolimus, Everolimus) - MOA

  • Drugs form complex with FKBP
  • FKBP/drug complex inhibits IL-2 mediated activation of mTor kinase (T-cell signal 2)
  • Inhibits IL-2 stimulated protein synthesis, cell proliferation, and survival
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

mTor Inhibitors (Sirolimus, Everolimus) - Adverse Effects

  • __triglyceridemia
  • __cholesterolemia
  • Increased __ disease
  • Increased risk of __
  • Anemia, thrombocytopenia, and leukopenia
  • Decreased __ healing
  • Teratogenic
  • Increased risk of __
  • Increased risk of __
A

mTor Inhibitors (Sirolimus, Everolimus) - Adverse Effects

  • Hypertriglyceridemia
  • Hypercholesterolemia
  • Increased lung disease
  • Increased risk of diabetes
  • Anemia, thrombocytopenia, and leukopenia
  • Decreased wound healing
  • Teratogenic
  • Increased risk of infections
  • Increased risk of malignancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

mTor Inhibitors (Sirolimus, Everolimus) - Misc

  • Metabolized by __
  • Many drug interactions
  • Contraindicated in __
  • NOT RECOMMENDED in __ transplantation (risk anastomotic dehiscence), __ transplantation (risk __ artery thrombosis)
A

mTor Inhibitors (Sirolimus, Everolimus) - Misc

  • Metabolized by CYP3A4
  • Many drug interactions
  • Contraindicated in pregnancy
  • NOT RECOMMENDED in lung transplantation (risk anastomotic dehiscence), liver transplantation (risk hepatic artery thrombosis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Rabbit anti-thymocyte globulin - Indications

-Induction __therapy

A

Rabbit anti-thymocyte globulin - Indications

-Induction immunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Rabbit anti-thymocyte globulin - MOA

  • Rabbit __clonal antibodies specific for human __
  • Depletes __ from the blood
A

Rabbit anti-thymocyte globulin - MOA

  • Rabbit polyclonal antibodies specific for human lymphocytes
  • Depletes lymphocytes from the blood
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Rabbit anti-thymocyte globulin - Adverse Effects

  • __ release syndrome
  • __penia
A

Rabbit anti-thymocyte globulin - Adverse Effects

  • Cytokine release syndrome
  • Leukopenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Alemtuzumab - Indications

-Induction __therapy

A

Alemtuzumab - Indications

-Induction immunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Alemtuzumab - MOA - Binds to CD__ expressed on t-cells, b-cells, macrophages, NK cells, and granulocytes - Depletes cells from the blood by __-__ lysis
Alemtuzumab - MOA - Binds to CD52 expressed on t-cells, b-cells, macrophages, NK cells, and granulocytes - Depletes cells from the blood by Ab-mediated lysis
26
Alemtuzumab - Adverse Effects - **__ release syndrome** - __penia - Can take over ____ for immune system to recover
Alemtuzumab - Adverse Effects - **Cytokine release syndrome** - Leukopenia - Can take over 1 yr for immune system to recover
27
Basiliximab - Indications -Induction __therapy
Basiliximab - Indications -Induction immunotherapy
28
Basiliximab - MOA - Antagonist of the IL-__ - Blocks __ proliferation
Basiliximab - MOA - Antagonist of the IL-2R - Blocks t-cell proliferation
29
IVIG - Indications -Provide short-lived __ immunity to patients with deficiency in __ immune system (e.g., hypogammaglobinemia)
IVIG - Indications -Provide short-lived humoral immunity to patients with deficiency in humoral immune system (e.g., hypogammaglobinemia)
30
IVIG - MOA - Pooled __ from healthy individuals - Provides patient with __ from healthy immunized donors to provide immunity to common pathogens
IVIG - MOA - Pooled Ig from healthy individuals - Provides patient with Ig from healthy immunized donors to provide immunity to common pathogens
31
Rho (D) - Indications -Prevention of __ disease of the newborn in newborns born to __ females
Rho (D) - Indications -Prevention of hemolytic disease of the newborn in newborns born to Rh- females
32
Rho (D) - MOA - Purified Ig to ____ antigen - Given to __ mother at 28 weeks and 72 hours post-pregnancy to deplete any fetal __ in maternal blood, to prevent the mother from generating an __ response to fetal __
Rho (D) - MOA - Purified Ig to Rh (D) antigen - Given to Rh- mother at 28 weeks and 72 hours post-pregnancy to deplete any fetal RBC in maternal blood, to prevent the mother from generating an immune response to fetal RBC
33
Hyperimmune Ig - Indications -To provide rapid specific __ immunity to specific viruses and/or toxins
Hyperimmune Ig - Indications -To provide rapid specific antibody immunity to specific viruses and/or toxins
34
Hyperimmune Ig - MOA - Purified __ to specific antigens purified from healthy volunteers - Given __ to patients in order to promote clearance of virus/toxin
Hyperimmune Ig - MOA - Purified Ig to specific antigens purified from healthy volunteers - Given IV to patients in order to promote clearance of virus/toxin
35
Ipilimumab - Indications -Tx of late-stage __
Ipilimumab - Indications -Tx of late-stage melanoma
36
Ipilimumab - MOA - Antibody specific for __ - Antagonizes the negative regulatory __ protein responsible for down-regulating activated __ - Enhances __ response
Ipilimumab - MOA - Antibody specific for CTLA4 - Antagonizes the negative regulatory CTLA4 protein responsible for down-regulating activated T-cells - Enhances T-cell response
37
Ipilimumab - Adverse Effects -Potential for __ autoimmune response (can be fatal)
Ipilimumab - Adverse Effects -Potential for RARE autoimmune response (can be fatal)
38
Pembrolizumab/Nivolumab - Indications -Tx of late-stage __
Pembrolizumab/Nivolumab - Indications -Tx of late-stage melanoma
39
Pembrolizumab/Nivolumab - MOA - Antibody specific for the __ protein, which is a __ regulatory receptor expressed on activated __ that is responsible for down-regulating __ responses - The __ ligand __ is expressed on __ cells - this is a mechanism for __ cells to avoid the immune response - These antibody drugs block __/__ interactions, blocking the inhibitory signal and leading to enhanced __ immune responses
Pembrolizumab/Nivolumab - MOA - Antibody specific for the PD1 protein, which is a negative regulatory receptor expressed on activated t-cells that is responsible for down-regulating t-cell responses - The PD1 ligand PD-L1 is expressed on tumor cells - this is a mechanism for tumor cells to avoid the immune response - These antibody drugs block PD1/PD1-L1 interactions, blocking the inhibitory signal and leading to enhanced tumor immune responses
40
Methotrexate - Indications -Tx of autoimmune diseases - especially __ __
Methotrexate - Indications -Tx of autoimmune diseases - especially rheumatoid arthritis
41
Methotrexate - MOA - Inhibition of __ __ to inhibit __ proliferation - __ mechanism of immunosuppression
Methotrexate - MOA - Inhibition of dihydrofolate reductase to inhibit lymphocyte proliferation - Indirect mechanism of immunosuppression
42
Methotrexate - Adverse Effects - __ toxicity - __ toxicity - __ toxicity - __ disease - __ suppression - __toxicity - __genic
Methotrexate - Adverse Effects - Renal toxicity - Hepatic toxicity - GI toxicity - Lung disease - BM suppression - Neurotoxicity - Teratogenic
43
Methotrexate - Misc -Contraindicated in __
Methotrexate - Misc -Contraindicated in pregnancy
44
Cyclophophamide - Indications - To prevent __ rejection - To prevent __ - Tx of __ cases of autoimmune disease
Cyclophophamide - Indications - To prevent graft rejection - To prevent GvHD - Tx of severe cases of autoimmune disease
45
Cyclophophamide - MOA - __ chemotherapeutic agent - ____ DNA, RNA, and proteins - Inhibits __ proliferation - Promotes __
Cyclophophamide - MOA - Alkylation chemotherapeutic agent - Cross-links DNA, RNA, and proteins - Inhibits cell proliferation - Promotes apoptosis
46
Cyclophophamide - Adverse Effects - __ suppression - __ toxicity - Increased risk of __ - Increased risk of __ - __genic (male/female)
Cyclophophamide - Adverse Effects - BM suppression - GI toxicity - Increased risk of infections - Increased risk of malignancy - Teratogenic (male/female)
47
Cyclophophamide - Misc -Contraindicated in __, women who wish to __ __, and men who wish to __ __
Cyclophophamide - Misc -Contraindicated in pregnancy, women who wish to become pregnant, and men who wish to become fathers
48
Chlorambucil - Indications -Sometimes used in the tx of __ diseases
Chlorambucil - Indications -Sometimes used in the tx of autoimmune diseases
49
Chlorambucil - MOA - __ chemotherapeutic agent - ____ DNA, RNA, and proteins - Inhibits __ proliferation - Promotes __
Chlorambucil - MOA - Alkylation chemotherapeutic agent - Cross-links DNA, RNA, and proteins - Inhibits cell proliferation - Promotes apoptosis
50
Chlorambucil - Adverse Effects - __ suppression - __ toxicity - Increased risk of __ - Increased risk of __ - __genic (male/female)
Chlorambucil - Adverse Effects - BM suppression - GI toxicity - Increased risk of infections - Increased risk of malignancy - Teratogenic (male/female)
51
Chlorambucil - Misc -Contraindicated in __, women who wish to __ __, and men who wish to __ __
Chlorambucil - Misc -Contraindicated in pregnancy, women who wish to become pregnant, and men who wish to become fathers
52
Fingolimod - Indications -Tx of relapsing-remitting __ __
Fingolimod - Indications -Tx of relapsing-remitting multiple sclerosis
53
Fingolimod - MOA - __ analog - Binds to 51P receptor to promote sequestration of __ in the lymph node, thereby preventing __ entry to CNS
Fingolimod - MOA - Sphingosine analog - Binds to 51P receptor to promote sequestration of lymphocytes in the lymph node, thereby preventing lymphocyte entry to CNS
54
Fingolimod - Adverse Effects - **__arrhythmia** - **__ __** - Increased risk of __ __ __ infection (potentially fatal) - Increased risk of __
Fingolimod - Adverse Effects - **Bradyarrhythmia** - **AV block** - Increased risk of varicella zoster virus infection (potentially fatal) - Increased risk of malignancy
55
Natalizumab - Indications -Tx of relapsing-remitting __ __
Natalizumab - Indications -Tx of relapsing-remitting multiple sclerosis
56
Natalizumab - MOA - Binds __ __ adhesion molecule - Prevents entry of __ into the CNS
Natalizumab - MOA - Binds alpha4 integrin adhesion molecule - Prevents entry of lymphocytes into the CNS
57
Natalizumab - Adverse Effects -**Increased risk of __ - especially if: a) prior use of immunosuppression, b) seropositive for __ virus, c) chronic treatment**
Natalizumab - Adverse Effects -**Increased risk of PML - especially if: a) prior use of immunosuppression, b) seropositive for JC virus, c) chronic treatment**
58
Interferon beta - Indications -Tx of relapsing-remitting __ __
Interferon beta - Indications -Tx of relapsing-remitting multiple sclerosis
59
Interferon beta - MOA - Activates __ beta receptors - Alters expression of __ gene expression - Inhibits entry of __ cells into CNS
Interferon beta - MOA - Activates IFN beta receptors - Alters expression of pro-inflammatory gene expression - Inhibits entry of inflammatory cells into CNS
60
Glatiramer acetate - Indications -Tx of relapsing-remitting __ __
Glatiramer acetate - Indications -Tx of relapsing-remitting multiple sclerosis
61
Glatiramer acetate - MOA - Polymer of 4 amino acids found in __ __ __ (MBP) - Production of specific suppressor __ that suppress inflammation in the __
Glatiramer acetate - MOA - Polymer of 4 amino acids found in myelin basic protein (MBP) - Production of specific suppressor T-cells that suppress inflammation in the CNS
62
Drugs covered in this lecture - Glucocorticoids/steroids: __/__ - Proliferation inhibitors and anti-metabolites: __, __ __ - Immunophilin-binding drugs - inhibitors of t-cell signaling pathways: calcineurin inhibitors (__, __), mTOR inhibitors (__, __) - Other anti-proliferative drugs used for immunosuppression: __, __, __ -Antibodies for induction immunosuppression: __ __ __-__ __, __, __ - Misc immunosuppressive drugs used in the tx of RR-multiple sclerosis: __, __, __, __ - Passive immunization IG: __, __, __ - Immune checkpoint inhibitors: __, __ and __
Drugs covered in this lecture - Glucocorticoids/steroids: prednisone/prednisolone - Proliferation inhibitors and anti-metabolites: azathioprine, mycophenolate mofetil - Immunophilin-binding drugs - inhibitors of t-cell signaling pathways: calcineurin inhibitors (cyclosporin, tacrolimus), mTOR inhibitors (sirolimus, everolimus) - Other anti-proliferative drugs used for immunosuppression: methotrexate, cyclophosphamide, chlorambucil -Antibodies for induction immunosuppression: rabbit polyclonal anti-thymocyte globulin, alemetzumab, basiliximab - Misc immunosuppressive drugs used in the tx of RR-multiple sclerosis: fingolimod, natalizumab, interferon, glatiramer - Passive immunization IG: IVIG, Rho(D) Ig, Hyperimmune Ig - Immune checkpoint inhibitors: ipilimumab, nivolumab and pembrozilmab

Pharmacology S1 Exam 5 (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions